West Pharmaceutical Services (WST) Asset Writedowns and Impairment (2011 - 2026)

West Pharmaceutical Services has disclosed Asset Writedowns and Impairment across 9 years of filings, most recently posting $300000.0 for Q1 2026.

• Asset Writedowns and Impairment for Q1 2026 came in at $300000.0, changed 0.0% year-over-year; the trailing twelve-month figure through Mar 2026 was $11.7 million (up 67.14% YoY), and the FY2025 annual result was $11.7 million, up 60.27% from the prior year.
• Asset Writedowns and Impairment came in at $300000.0 for Q1 2026 at West Pharmaceutical Services, down from $7.3 million in the prior quarter.
• In the past five years, Asset Writedowns and Impairment ranged from a high of $7.3 million in Q4 2025 to a low of $200000.0 in Q2 2022.
• The 5-year median for Asset Writedowns and Impairment is $1.4 million (2022), against an average of $2.2 million.
• Across the five-year window, Asset Writedowns and Impairment sank 80.0% in 2024 and jumped 1166.67% in 2025, its largest moves.
• West Pharmaceutical Services' Asset Writedowns and Impairment stood at $4.6 million in 2022, then sank by 41.3% to $2.7 million in 2023, then soared by 100.0% to $5.4 million in 2024, then jumped by 35.19% to $7.3 million in 2025, then tumbled by 95.89% to $300000.0 in 2026.
• The last three Asset Writedowns and Impairment figures came in at $300000.0 (Q1 2026), $7.3 million (Q4 2025), and $300000.0 (Q3 2025), per Business Quant data.